Literature DB >> 24690055

Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.

Fiona L Shand1, Carolyn Day, William Rawlinson, Louisa Degenhardt, Nicholas G Martin, Elliot C Nelson.   

Abstract

BACKGROUND: In Australia about half of the people who inject drugs (PWID) are hepatitis C (HCV) antibody positive (anti-HCV+). The prevalence among opioid substitution treatment (OST) clients specifically is unclear, despite OST clinics being a potential setting for HCV care. This study aimed to report the prevalence of HCV among a large sample of NSW OST clients, understand whether HCV testing is translating into knowledge of status, and identify the correlates of inaccurate self-reporting of HCV status.
METHODS: Participants completed an interview that included self-reported HCV status. Participants also provided a blood sample that was tested for HCV IgG antibodies, and for viral load using a quantitative real-time reverse-transcriptase polymerase chain reaction. Valid interviews and viable blood sample were provided by 1,484 participants. Logistic regression modelling was used to identify independent predictors of knowledge of HCV antibody status.
RESULTS: Overall, 84% of participants were anti-HCV+. Of these, 65% were RNA+. Four per cent of anti-HCV negative participants were RNA+. One-quarter of anti-HCV+ participants did not know their status or reported it incorrectly, compared with 14.5% of anti-HCV negative participants.
CONCLUSION: The prevalence of HCV in this sample was higher than that found among other samples of people who inject drugs, suggesting the need for greater prevention efforts with OST clients. Anti-HCV+ individuals are less accurate at reporting their HCV status than those who are anti-HCV-. Inaccurate knowledge is associated with different variables for anti-HCV+ vs. anti-HCV- individuals. There are opportunities to improve knowledge of HCV status and to therefore improve health outcomes and reduce transmission among this at-risk population.
© 2014 The Authors. ANZJPH © 2014 Public Health Association of Australia.

Entities:  

Keywords:  HCV; hepatitis C virus; injecting drug users; injecting risks; viral load

Mesh:

Substances:

Year:  2014        PMID: 24690055      PMCID: PMC4546838          DOI: 10.1111/1753-6405.12173

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  18 in total

1.  Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

Authors:  Jason Grebely; Gail V Matthews; Andrew R Lloyd; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2013-05-31       Impact factor: 9.079

2.  Self-reported hepatitis C virus antibody status and risk behavior in young injectors.

Authors:  Holly Hagan; Jennifer Campbell; Hanne Thiede; Steffanie Strathdee; Lawrence Ouellet; Farzana Kapadia; Sharon Hudson; Richard S Garfein
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

3.  HCV status knowledge and risk behaviours amongst intravenous drug users.

Authors:  G Vidal-Trécan; J Coste; I Varescon-Pousson; B Christoforov; A Boissonnas
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

4.  Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.

Authors:  Peter A White; Yong Pan; Anthony J Freeman; George Marinos; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  A validity study of the SSAGA--a comparison with the SCAN.

Authors:  M Hesselbrock; C Easton; K K Bucholz; M Schuckit; V Hesselbrock
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

6.  Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.

Authors:  Maryam Alavi; Jason Grebely; Michelle Micallef; Adrian J Dunlop; Annie C Balcomb; Carolyn A Day; Carla Treloar; Nicky Bath; Paul S Haber; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

7.  National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia.

Authors:  Adam R Winstock; Caroline M Anderson; Janie Sheridan
Journal:  Med J Aust       Date:  2006-06-05       Impact factor: 7.738

8.  A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA.

Authors:  K K Bucholz; R Cadoret; C R Cloninger; S H Dinwiddie; V M Hesselbrock; J I Nurnberger; T Reich; I Schmidt; M A Schuckit
Journal:  J Stud Alcohol       Date:  1994-03

9.  Modelling the hepatitis C virus epidemic in Australia.

Authors:  Karina Razali; Hla Hla Thein; Jane Bell; Mark Cooper-Stanbury; Kate Dolan; Greg Dore; Jacob George; John Kaldor; Maria Karvelas; Jiong Li; Lisa Maher; Sharyn McGregor; Margaret Hellard; Fiona Poeder; Julianne Quaine; Kim Stewart; Helen Tyrrell; Martin Weltman; Owen Westcott; Alex Wodak; Matthew Law
Journal:  Drug Alcohol Depend       Date:  2007-07-31       Impact factor: 4.492

10.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users.

Authors:  Carol F Kwiatkowski; Karen Fortuin Corsi; Robert E Booth
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.